NCT04314544已完成3 期
A Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 508
- 试验地点
- 148
- 主要终点
- The proportion of subjects who achieve American College of Rheumatology [ACR20]
研究概览
简要总结
This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has provided written informed consent.
- •Subject is ≥ 18 years of age at time of Screening.
- •RF and anti-CCP Ab negative.
- •Subjects must have prior exposure to anti-TNF agent(s) use for the treatment of PsO or PsA.
排除标准
- •Subject has a planned surgical intervention between Baseline and the Week 24 evaluation for a pretreatment condition.
- •Subject has an active infection or history of infections as follows:
- •any active infection for which systemic anti-infectives were used within 28 days prior to first IMP dose, with the last dose having been received within 7 days of Screening,
- •a serious infection, defined as requiring hospitalization or IV anti-infectives within 8 weeks prior to the first IMP dose, with the last dose having been received within 7 days of Screening,
- •recurrent or chronic infections, e.g., chronic pyelonephritis, chronic osteomyelitis, bronchiectasis, or other active infection that, in the opinion of the Investigator, might cause this study to be detrimental to the subject.
- •Subject has a known history of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.
- •Subject had myocardial infarction, unstable angina pectoris, or ischemic stroke within the past 6 months prior to the first IMP dose.
- •Subject has any active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma.
- •Subject has a history of malignancy within 5 years from the time of Screening EXCEPT treated and considered cured cutaneous basal or squamous cell carcinoma, in situ cervical carcinoma, OR in situ breast ductal carcinoma.
- •Subjects with a history of alcohol or drug abuse in the previous 2 years.
- •Female subjects of childbearing potential who do not agree to abstain from heterosexual activity or practice a dual method of contraception, for example, a combination of the following: (1) oral contraceptive, depo progesterone, or intrauterine device; and (2) a barrier method (condom or diaphragm). Male subjects with female partners of childbearing potential who are not using birth control as described above must use a barrier method of contraception (e.g., condom) if not surgically sterile (i.e., vasectomy). Contraceptive methods must be practiced upon entering the study and through 17 weeks after the last dose of IMP. If a subject discontinues prematurely, the contraceptive method must be practiced for 17 weeks following final administration of IMP. A FSH test should be performed to confirm menopause for those women with no menses for less than 1 year.
- •Subject currently enrolled in another investigational device/procedure or drug study, or Baseline of this study is less than 30 days or 5 half-lives (whichever is longer) since ending another investigational device/procedure or drug study(s), or receiving other investigational agent(s).
- •Subject previously has been enrolled (randomized) in this study.
- •Subject has any kind of disorder that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures.
- •Donation or loss of 400 mL or more of blood within 8 weeks before dosing.
- •Subjects who have been placed in an institution on official or judicial orders.
- •Subjects who are related to or dependent on the Investigator, Sponsor, or study site such that a conflict of interest could arise.
研究组 & 干预措施
Arm A
Experimental
干预措施: TILD (Drug)
Arm B
Placebo Comparator
干预措施: matching placebo injections (Drug)
结局指标
主要结局
The proportion of subjects who achieve American College of Rheumatology [ACR20]
时间窗: at week 24
the proportion of subjects achieving a 20% reduction from Baseline in response criteria
次要结局
- The proportion of subjects achieving Psoriasis Area and Severity Index 75 response among subjects with Body surface area ≥3% at baseline(at Weeks 24)
- The change from Baseline in Leeds Dactylitis Index(at Week 24)
- The proportion of subjects who achieve a disease activity score-C-reactive protein < 3.2(at Week 24)
- The proportion of subjects with active Psoriasis and Body surface area ≥3%(at Week 24)
- The change from Baseline in subjects with active Psoriasis and Body surface area ≥ 3% ("those with involvement of nails" )(at Week 24)
- In subjects with active Psoriasis and Body surface area ≥3% those with involvement of nails , the change from Baseline in nail psoriasis severity index(at Week 52)
- Change from baseline in health assessment questionnaire - disability index (HAQ-DI) score(at Week 24)
- The proportion of subjects achieving American College of Rheumatology [ACR70](at Week 24)
- The change from Baseline in the van der Heijde modified total Sharp score(at Week 16)
- The change from Baseline in van der Heijde modified total Sharp score(at Week 52)
- The proportion of subjects with the change in van der Heijde modified total Sharp score <0 and < 0.5(at Week 52)
- The proportion of subjects achieving American College of Rheumatology [ACR50](at Week 24)
- Change from Baseline in American College of Rheumatology Response Criteria Components Score(at Week 24)
- change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index(at Week 24)
- The change from Baseline in van der Heijde modified Sharp sub-scores (erosion score and joint space narrowing score)(at Week 52)
- The proportion of subjects with the Change in van der Heijde modified total Sharp score <0 and < 0.5(at Week 24.)
- The proportion of subjects achieving American College of Rheumatology [ACR20, ACR50 and ACR70](at week 52)
- The change from Baseline in American College of Rheumatology Response Criteria Components Score(at Week 52)
- The change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index(at Week 52)
- The change from Baseline(at Week 52)
- change from Baseline in Leeds Enthesitis Index(at Week 24)
- In subjects with active Psoriasis and Body surface area ≥3%, the change from Baseline in Physician Global Assessment-Psoriasis(at Week 52)
- The change from Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components(Weeks 24 and 52)
- The proportion of subjects who achieve a Disease Activity Score(28 [joints]-C-reactive protein) < 3.2(at Week 52)
- In subjects with active Psoriasis and Body surface area ≥3%, the proportion of subjects(at Week 52)
- The change from Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scores(at Week 24)
- The change from Baseline in the van der Heijde modified total Sharp score(at Week 24)
- The change from Baseline in van der Heijde modified Sharp sub-scores (erosion score and joint space narrowing score)(at Week 24)
研究者
研究点 (148)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLCTreatment-naive Advanced Non-small Cell Lung CancerNCT03856411Shanghai Junshi Bioscience Co., Ltd.465
已完成
3 期
A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive DisorderMajor Depressive DisorderNCT03672175Biogen581
进行中（未招募）
3 期
Phase III Study of KX-826 With Adult Male Patients With AGAAndrogenetic AlopeciaNCT06126965Suzhou Kintor Pharmaceutical Inc,740
Unknown
3 期
A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19COVID-19NCT04425460Zhejiang Hisun Pharmaceutical Co. Ltd.256
已完成
3 期
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)Recurrent Vulvovaginal CandidiasisNCT04029116Scynexis, Inc.440